David A. Sallman

机构：Moffitt Cancer Center · ORCID：0000-0003-0504-8233

发表论文 881 篇 · 总被引 9643 次 · h-index 47

代表论文

Data from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2026 · 被引 1)
Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms (2026 · Blood)
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study (2026 · Journal of Clinical Oncology)
Supplemental Table 9 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2026)
Supplemental Table 9 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2026)
Supplemental Table 2 from Phase 1 Study of KITE-222, an Autologous CLL-1–Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (2026)